CPIC® Guideline for Serotonin Reuptake Inhibitor . . . Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants Updates since publication: None Tables provided in the main manuscript of the guideline:
Clinical Pharmacogenetics Implementation Consortium (CPIC . . . This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability
Clinical Pharmacogenetics Implementation Consortium (CPIC . . . We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing
CPIC Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4 and HTR2A . . . This new guideline updates the CPIC guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19, and includes additional Serotonin Reuptake Inhibitor Antidepressants and three additional genes, CYP2B6, HTR2A, and SLC6A4
Clinical Pharmacogenetics Implementation Consortium (CPIC . . . This document updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and selective serotonin reuptake inhibitor (SSRI) antidepressants (1) The current guideline includes updated evidence
Antidepressant Pharmacogenetics - American Journal of Psychiatry This growth can be attributed in part to a top pharmacogenetics body, the Clinical Pharmacogenetics Implementation Consortium (CPIC), which has published guidelines on the use of hepatic metabolizer status genotyping (cytochrome P450 CYP2D6 and CYP2C19) in dosing various antidepressants CPIC is a non–industry funded group of international
Comparison of antidepressants effectiveness and side effects . . . The Clinical Pharmacogenetics Implementation Guidelines (CPIC) for TCAs recommend avoiding the use of amitriptyline and similar medications in patients who are Ultrarapid metabolisers of either CYP2C19 or CYP2D6 enzyme due to potential lack of efficacy